CSC Wins $19.7 Million Award for Advanced Development of Biodefense Vaccines
EL SEGUNDO, Calif. -- Computer Sciences Corporation (CSC) announced that DVC LLC, a CSC company, has been awarded approximately $19.7 million in grants and contract modifications from the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health.
The new grants and contract modifications are in addition to the award of an $11 million grant to CSC from the NIAID in September 2003.
Under the terms of these new awards, DVC will continue the advanced development of vaccines for tularemia, botulism and Venezuelan equine encephalitis. The company will perform stability testing and manufacture a current good manufacturing practices pilot batch of live tularemia vaccine. DVC also will conduct a phase 2 clinical trial for its Venezuelan equine encephalitis vaccine candidate and continue development of a stable multivalent botulinum vaccine candidate.
NIAID is a component of the National Institutes of Health, an agency of the U.S. Department of Health and Human Services. NIAID conducts and supports research that strives to understand, treat and ultimately prevent the myriad of infectious, immunologic and allergic diseases that threaten hundreds of millions of people worldwide.
DVC is a biopharmaceutical company dedicated to the development and licensure of safe and efficacious biodefense vaccines and therapeutics. DVC is part of CSCs Enforcement, Security and Intelligence organization, which CSC created in 2002 to support programs enhancing U.S. security.
Source: Computer Sciences Corporation
Newsletter
Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.
Reducing Hidden Risks: Why Sharps Injuries Still Go Unreported
July 18th 2025Despite being a well-known occupational hazard, sharps injuries continue to occur in health care facilities and are often underreported, underestimated, and inadequately addressed. A recent interview with sharps safety advocate Amanda Heitman, BSN, RN, CNOR, a perioperative educational consultant, reveals why change is overdue and what new tools and guidance can help.
New Study Explores Oral Vancomycin to Prevent C difficile Recurrence, But Questions Remain
July 17th 2025A new clinical trial explores the use of low-dose oral vancomycin to prevent Clostridioides difficile recurrence in high-risk patients taking antibiotics. While the data suggest a possible benefit, the findings stop short of statistical significance and raise red flags about vancomycin-resistant Enterococcus (VRE), underscoring the delicate balance between prevention and antimicrobial stewardship.
What Lies Beneath: Why Borescopes Are Essential for Verifying Surgical Instrument Cleanliness
July 16th 2025Despite their smooth, polished exteriors, surgical instruments often harbor dangerous contaminants deep inside their lumens. At the HSPA25 and APIC25 conferences, Cori L. Ofstead, MSPH, and her colleagues revealed why borescopes are an indispensable tool for sterile processing teams, offering the only reliable way to verify internal cleanliness and improve sterile processing effectiveness to prevent patient harm.
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence
July 15th 2025New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.
